PB1795: MESENCHYMAL STROMAL CELL-DEPENDENT ADHESION PATHWAYS PROTECT AML CELLS FROM VENETOCLAX-INDUCED APOPTOSIS

PB1795: MESENCHYMAL STROMAL CELL-DEPENDENT ADHESION PATHWAYS PROTECT AML CELLS FROM VENETOCLAX-INDUCED APOPTOSIS

Bibliographic Details
Main Authors:	Marilena Ciciarello, Giulia Rosaci, Giulia Corradi, Samantha Bruno, Jacopo Nanni, Michele Cavo, Antonio Curti
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000974036.37075.c8

Similar Items

Ex vivo characterization of acute myeloid leukemia patients undergoing hypomethylating agents and venetoclax regimen reveals a venetoclax-specific effect on non-suppressive regulatory T cells and bona fide PD-1+TIM3+ exhausted CD8+ T cells
by: Giulia Corradi, et al.
Published: (2024-05-01)

The Yin and Yang of the Bone Marrow Microenvironment: Pros and Cons of Mesenchymal Stromal Cells in Acute Myeloid Leukemia
by: Marilena Ciciarello, et al.
Published: (2019-10-01)

Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival
by: Giulia Corradi, et al.
Published: (2018-10-01)

P1375: VENETOCLAX MODULATES TIM-3 EXPRESSION ON CD8 T CELLS IN ACUTE MYELOID LEUKEMIA PATIENTS
by: Darina Ocadlikova, et al.
Published: (2023-08-01)

The Human Mesenchymal Stromal Cell-Derived Osteocyte Capacity to Modulate Dendritic Cell Functions Is Strictly Dependent on the Culture System
by: Sara Trabanelli, et al.
Published: (2015-01-01)

Venetoclax for AML: changing the treatment paradigm
by: Daniel A. Pollyea, et al.
Published: (2019-12-01)

PB2413: SALVAGE THERAPY WITH VENETOCLAX AND A HYPOMETHYLATING AGENT FOR PATIENTS WITH AML RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
by: Inna Shaforostova, et al.
Published: (2023-08-01)

Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation
by: Maansi Joshi, et al.
Published: (2021-03-01)

MRD in Venetoclax-Based Treatment for AML: Does it Really Matter?
by: Massimo Bernardi, et al.
Published: (2022-07-01)

Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML
by: Xing-yu Cao, et al.
Published: (2023-12-01)

P419: IDENTIFICATION OF NOVEL THERAPEUTIC OPTIONS FOR VENETOCLAX-RESISTANT AML CELLS THROUGH DRUG REPURPOSING
by: A. Ladungova, et al.
Published: (2022-06-01)

AML alters bone marrow stromal cell osteogenic commitment via Notch signaling
by: Chiara Tomasoni, et al.
Published: (2023-12-01)

Investigating resistance to 5-Azacytidine and Venetoclax in PDX models of MDS/AML
by: Petra Bašová, et al.
Published: (2025-01-01)

PB1860: HIGH EFFICACY OF HYPOMETHYLATING AGENTS PLUS VENETOCLAX COMBINATION THERAPY IN ELDERLY PATIENTS AML PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY: A REAL-LIFE EXPERIENCE.
by: Maria Elena Zannier, et al.
Published: (2023-08-01)

Crosstalk between AML and stromal cells triggers acetate secretion through the metabolic rewiring of stromal cells
by: Nuria Vilaplana-Lopera, et al.
Published: (2022-09-01)

PB1905: REAL-WORLD EXPERIENCE OF LOW-DOSE VENETOCLAX WITH AZACITIDINE FOR UNFIT AML PATIENTS(≥60Y) WITH LOW LEUKOCYTE COUNT
by: Wenjian Wei, et al.
Published: (2023-08-01)

ONC213: a novel strategy to resensitize resistant AML cells to venetoclax through induction of mitochondrial stress
by: Jenna L. Carter, et al.
Published: (2025-01-01)

P426: HDAC INHIBITORS RESTORE SENSITIVITY TO VENETOCLAX AND NAVITOCLAX IN AML CELLS RESULTING IN THE IRREVERSIBLE DNA DAMAGE
by: Elmira Khabusheva, et al.
Published: (2023-08-01)

Venetoclax combination therapy induces deep AML remission with eradication of leukemic stem cells and remodeling of clonal haematopoiesis
by: Romain Vazquez, et al.
Published: (2021-03-01)

Bone marrow mesenchymal/fibroblastic stromal cells induce a distinctive EMT-like phenotype in AML cells
by: N. Nojszewska, et al.
Published: (2023-09-01)

P555: OLUTASIDENIB IN POST-VENETOCLAX PATIENTS WITH MUTANT IDH1 AML
by: Jorge Cortes, et al.
Published: (2023-08-01)

FOXM1-AKT Positive Regulation Loop Provides Venetoclax Resistance in AML
by: Mikhail S Chesnokov, et al.
Published: (2021-07-01)

PB1925: VENETOCLAX IN COMBINATION WITH AZACITIDINE OR LOW-DOSE CYTARABINE IN PATIENTS WITH HIGH-RISK MDS AND AML - EXPERIENCE OF A CZECH HAEMATOLOGY CENTRE.
by: L. Minarik, et al.
Published: (2022-06-01)

P485: TARGETING HISTONE LYSINE-SPECIFIC DEMETHYLASES BY JIB-04 IMPROVES RESPONSE OF AML CELLS TO VENETOCLAX TREATMENT
by: K. Wohlan, et al.
Published: (2022-06-01)

P1246: DIFFERENTIAL ROLE OF MICROENVIRONMENT AND STROMAL-CELL INDUCED VENETOCLAX RESISTANCE IN MANTLE CELL LYMPHOMA
by: P. Andersen, et al.
Published: (2022-06-01)

P534: AZACITIDINE PLUS VENETOCLAX FOR THE TREATMENT OF RELAPSED AND FIRST-LINE AML PATIENTS
by: S. Garciaz, et al.
Published: (2022-06-01)

AML with BCR-ABL1 Fusion treated with Imatinib, a Hypomethylating Agent and Venetoclax
by: Soon Khai Low, et al.
Published: (2022-01-01)

PB1820: CD47-BLOCKER TTI-622 COMBINED WITH AZACITIDINE IN PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA (AML) AND WITH AZACITIDINE + VENETOCLAX IN ELDERLY OR UNFIT PATIENTS WITH TP53-WILDTYPE AML
by: N. Daver, et al.
Published: (2022-06-01)

PB2168: BRUSATOL INDUCES APOPTOSIS IN AGGRESSIVE LYMPHOMA CELLS IN VITRO AND SYNERGIZES WITH VENETOCLAX
by: M. Szmyra, et al.
Published: (2022-06-01)

P388: PREFERENTIAL SYNERGISTIC EFFECT OF INDISULAM IN COMBINATION WITH VENETOCLAX AND AZACYTIDINE IN AML CELLS WITH SF3B1 MUTATIONS.
by: P. Bernardo, et al.
Published: (2022-06-01)

EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax
by: Katie Fooks, et al.
Published: (2022-12-01)

PB1792: REPURPOSING OF ANTIBIOTICS INHIBITING MITOCHONDRIAL TRANSLATION IN COMBINATION WITH VENETOCLAX IN ACUTE MYELOID LEUKEMIA: FROM PRECLINICAL MODELS TO CLINICAL PRACTICE
by: Viviana Amato, et al.
Published: (2023-08-01)

Retinoic acid and proteotoxic stress induce AML cell death overcoming stromal cell protection
by: Francesca Liccardo, et al.
Published: (2023-08-01)

Gut Mesenchymal Stromal Cells in Immunity
by: Valeria Messina, et al.
Published: (2017-01-01)

The role of neural cell adhesion molecule in melanoma progression and mesenchymal stromal cells migration
by: Shi, Yu
Published: (2013)

PB1849: EARLY SALVAGE THERAPY WITH VENETOCLAX AND 10-DAY DECITABINE IS FEASIBLE AND SAFE IN REFRACTORY AML: RESULTS FROM 11 PATIENTS WITH EARLY INDUCTION FAILURE
by: Carla Borst, et al.
Published: (2023-08-01)

P564: HOMOHARRINGTONINE AND CYTARABINE COMBINED WITH VENETOCLAX (HAV) FOR ADULT PATIENTS WITH DE NOVO AML
by: Xiao-Hua Luo, et al.
Published: (2023-08-01)

P488: SAFETY AND EFFICACY OF VENETOCLAX PLUS “7 + 3” CHEMOTHERAPY IN NEWLY DIAGNOSED AML
by: Ioannis Mantzaris, et al.
Published: (2023-08-01)

Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
by: Hua Jin, et al.
Published: (2023-04-01)

Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/Mcl-1/p-Chk1 axis
by: Jingyi Zhang, et al.
Published: (2022-04-01)